Pyxis Oncology, Inc.

Healthcare · Biotechnology · United States

Last price 1.89 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 225.77M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; PYX-102, an investigational immunotherapeutic targeting KLRG1, an inhibitory receptor on T cells and NK cells, with potential for use as monotherapy or in combination treatments; and lead immuno-o...